… Patients were randomly assigned (1:1) to receive afatinib (40 mg … erlotinib (150 mg per day)
until disease progression. Endpoints included OS and safety; a post-hoc analysis of patients …

… erlotinib once daily plus 15 mg/kg intravenous bevacizumab once every 21 days, or 150 mg
oral erlotinib once daily, until disease progression or … subtype, and clinical disease stage. All …

… anti-tumor activity in patients with advanced non-small cell lung … of anlotinib maintenance
therapy in patients with advanced … drug: erlotinib, as switch maintenance for patients with any …

… patients were randomized (1:1) to E + RT (oral erlotinib 150 mg/d for 2 years or until disease
progression … 5 d/wk for 6 weeks from the first day of erlotinib) or EP + RT (etoposide 50 mg/m …

… equivalent to one-third of erlotinib 150 mg, is as effective as erlotinib 150 mg, erlotinib in
one-third of the standard MTD dose could maintain sufficient concentration and would also be …

… BEV (15mg/kg iv q3w) until disease progression or unacceptable toxicity. Center, ECOG PS
… We use cookies to help provide and enhance our service and tailor content. To update your …

… Our findings demonstrate that erlotinib is an effective neoadjuvant regimen in patients with
EGFR-mutant locally advanced NSCLC, paving the way for its extended use in neoadjuvant …

… Dose reduction for adverse events was allowed for erlotinib. Patients in both arms were
treated until disease progression or unacceptable toxicity or patient’s or physician’s motivated …

… of non–small cell lung cancer (NSCLC) patients with brain metastases. We assessed whether
concurrent erlotinib with WBRT is safe and benefits patients in a … by maintenance erlotinib …

… a phase III trial (AIO 0207) for advanced colorectal cancer.11, 12, 13 … disease progression
or death during osimertinib treatment, or the time from randomization until disease progression …